SCHEMBL12102740

SCHEMBL12102740

CC(C)(C)N1CC[C@H](C(=O)O)C1

nearest known ligand 0.46

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.43
NOTUM Q6P988 12/20 0.42
ALDH1A1 P00352 1/20 0.40
ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15188004 1.00 LMNA (0.46) LMNAPOLBNOTUMALDH1A1ATM
SCHEMBL11977462 1.00 LMNA (0.46) LMNAPOLBNOTUMALDH1A1ATM
SCHEMBL12102748 0.88 ALDH1A1 (0.49) LMNAPOLBALDH1A1
SCHEMBL21042943 0.88 ALDH1A1 (0.49) LMNAPOLBALDH1A1
SCHEMBL2606791 0.88 ALDH1A1 (0.49) LMNAPOLBALDH1A1
SCHEMBL4767761 0.87 LMNA (0.53) LMNAPOLBNOTUMALDH1A1
Hydrochloric Acid SCHEMBL21612902 0.86 ALDH1A1 (0.51) LMNAPOLBALDH1A1
Hydrochloric Acid SCHEMBL3541382 0.85 LMNA (0.52) LMNAPOLBALDH1A1
SCHEMBL25474851 0.83 ATM (0.37) LMNAPOLBATM
SCHEMBL25474849 0.83 ATM (0.37) LMNAPOLBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4249484-A1 CRYSTAL TYPE II OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR PREPARING SAME Lg Chem, Ltd. (KR) 2023-09-27 EP disclosed
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
US-20210386721-A1 SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2021-12-16 US disclosed
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 EP disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 US disclosed
US-8389508-B2 Heterocyclic compounds GLAXO GROUP LIMITED (GB) 2013-03-05 US disclosed
US-20110269738-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R LMNA 2192/4885POLB 4768/4885NOTUM 4460/4885
US-20110269738-A1 COMPOUNDS CYP11B2, CYP11B1, GPR119 LMNA 1443/4885POLB 3053/4885NOTUM 713/4885
US-20210386721-A1 SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS PDCD1, CD274, PDCD1LG2 LMNA 3009/4885POLB 2429/4885NOTUM 298/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R LMNA 2192/4885POLB 4768/4885NOTUM 4460/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR LMNA 1558/4885POLB 4794/4885NOTUM 4635/4885
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINE1, SERPINA3 LMNA 2098/4885POLB 593/4885NOTUM 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.